4c sS -t_e can be said to be a proven method of treating other It seems unlikely that surgery andr erapy, than a fairly small group of rather uncommon the main weapons in the anticancer armamen-cancers. But if we accept that surgery and. radiotarium for many years, will yield much in the way therapy are unlikely to be able to increase their of further improvements in the prognosis ofcancer effectiveness; that primary prevention of the bulk patients. Radiotherapy has demonstrated con-of common cancers is going to be achieved only in siderable advances in some areas, for example in the far distant future, if at all; and that secondary the treatment of stage 1, 2 and 3A Hodgkin's prevention, i.e. screening, is of doubtful practicdisease (Timothy et al. 1978) , and it has yet to be ability in most cancers and likely to remain so for clearly shown what can be achieved by high energy many yearsthen chemotherapy would appear to photon or heavy particle radiation. But in general, offer the only current opportunity to improve the given the continuance of the existing pattern of outlook for cancer patients. It must therefore be presentation of cancers, it seems likely that we will thoroughly evaluated and where there is evidence have to look elsewhere than surgery or radioof benefit in disease control it must be fully therapy for the means to improve on the present exploited. survival figures.
An increasing problem with cytotoxic chemo-Cytotoxic chemotherapy provides an alternative therapy is its cost (Berry & Bryan 1978) . Certainly or additional means of treatment which in some some of the drugs have high unit cost and intensive conditions has completely altered the picture of the chemotherapy produces incidental costs in the way disease. The progress made in the treatment of the of, for example, special nursing procedures and leukaemias, of advanced Hodgkin's disease and, to antibiotic cover. Estimates of the cost of treating a a lesser extent, of the non-Hodgkin lymphomas case of acute myeloid leukaemia in a special unit can largely be attributed to the use of chemorange from £2500 to £10 000, about a quarter of therapy on its own or in combination with radio-this being attributable to drugs. Lister, Cullen et al. 1978) .
advanced breast cancer were so treated the total The benefits of chemotherapy in these con-cost of drugs alone would come to something like ditions are clearprolonged remissions, fre-£16 million pounds a year. quently equating with cure, in diseases which Any consideration of costs should, of course, be previously carried a very high mortality. In some within the context of the overall cost ofcancer. The solid tumours there have been similar gainsestimate of NHS current expenditure on the diagtrophoblastic tumours, testicular tumours and in nosis and treatment of cancer in England in 1976 neuroblastoma and nephroblastoma. In the com-was £244 million, just over 500 of total current moner solid tumours of adult life, however, the expenditure on the NHS. Inpatient and outpatient benefits are tantalizingly ill-defined and uncertain. care accounted for about 95% of that total. Best Breast cancer is the only major adult solid tumour estimates suggest that about £7 million is paid out to show much promise (Bonadonna et al. 1976 ) annually in sickness and invalidity benefits to and even here the early indications of improved cancer sufferers and that about £25 million is the remission duration in those receiving chemocost of lost output attributable to the disease. therapy seem not to be holding up (Bonadonna et There are also of course financial losses due to al. 1977) . Indications of benefit in the other com-premature death which are much more difficult to mon cancerslung, for exampleare so far slight compute. The visible cost of cancer is therefore or nonexistent (Chahinian et al. 1977) . It is debat-something of the order of £276 million a year at able whether any real benefit accrues from extend-1976 prices. In that year drugs accounted for 6% of ing the survival time of a patient with lung cancer NHS expenditure on cancer compared with 2.5% from 6 months to 12 months if it means subjecting in 1968 and there is evidence that that percentage him to the discomforts of intensive chemotherapy has risen more steeply in the last 2 years. for a large part of that additional time.
Expenditure on drugs in specialist cancer units is Based on paper to Section of Oncology, 25 January 1978. Accepted 19 September 1978 0141-0768/79/010001-02/$01 .00/0 now a major budget item accounting for 10% or more of current expenditure. This is leading to considerable difficulties in some hospitals where the effects of the Resource Allocation Working © 1979 The Royal Society of Medicine r Party report and cash limits have curtailed the ability to meet such increases.
The increase in expenditure in real terms is no doubt due to several factors among which are the tendency to use higher doses of individual drugs or more drugs in combined regimens; real increases in the cost of some drugs; and the application of chemotherapy by an increasing number of clinicians to a progressively widening spectrum of cancers. These last two are probably the most important factors. There are now few cancers where chemotherapy is not being used to some degree, either speculatively or under clinical trial conditions; given the extreme complexity of many of the multi-drug regimens there seems much to be said on both clinical and economic grounds for them to be used primarily in the latter mode within the context of the multidisciplinary oncological team.
Increasing experience in the use of cytotoxic chemotherapy and in the control of toxicity have made this expansion feasible, and though results so far are perhaps rather disappointing, the possibility of a major advance in the management of solid tumours using cytotoxic drugs can by no means yet be discounted. This might come from the development of new ways of using existing drugs or from the discovery of new drugs.
The costs appear high but costs are relative. If, for example, there was clear evidence that spending £16 million on chemotherapy for breast cancer brought sufficient dividends in terms of lives saved or usefully prolonged then it might become a sustainable cost. If that cannot be demonstrated in respect of any cancer then the use of intensive chemotherapy becomes economically difficult to justify and difficult to justify also on clinical grounds in view of the high non-monetary costs of the treatment (British Medical Journal 1978) . The only way we can get the evidence required to make rational decisions on this is through good clinical trials. It is vitally important that there is a carefully coordinated programme of high quality clinical trials set up at the earliest opportunity in relation to any cancer where it is suggested that chemotherapy may be of benefit and for any new cytotoxic agent released for clinical use. It is an urgent problem and it is encouraging that coordination is already happening under the aegis of the Medical
Research Council and the Cancer Research
Campaign.
The results of these trials must of course be published as soon as a scientifically valid conclusion has been reached, but it is essential that early results are treated with the utmost caution. A very prolonged period of observation is necessary to demonstrate improved survival, the ultimate criterion of benefit, and long-term toxic effects (Williams & Carter 1978) : without good evidence on both counts a great deal of highly toxic and expensive therapy may be given to no avail.
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Dermatitis herpetiformis and gluten enteropathy: a unifying concept'
Reports associating dermatitis herpetiformis (DH) and gluten enteropathy first appeared a decade or so ago. However, difficulties remain in correlating the pathogenesis of the two conditions. In order to overcome these difficulties reference should be made to published work, but it is also. necessary to make some assumptions which remain to be verified. Forty years ago, coeliac or Gee's disease was regarded as serious. Emphasis was placed on the malnourished patient, the often severe alimentary disturbance and the fatty stool. Then dietary gluten was established as its cause and the flattened mucosa was revealed by jejunal biopsy. It was also shown that gluten enteropathy might exist in patients with few or no alimentary symptoms. This
